Corporate presentation outlines ProTide platform and lead programs
NuCana published a corporate presentation outlining its ProTide platform and lead oncology programs NUC-7738 and NUC-3373.
The presentation highlighted NuTide:701 data for NUC-7738, including a 41% disease control rate in efficacy-evaluable patients.
In the combination cohort, one patient showed a 55% tumor reduction, another achieved a 32% tumor reduction, and one had an ongoing complete metabolic response.
Cash and cash equivalents were about $25.9 million as of June 30, 2026, and cash runway was projected into 2029.
NCNA•
